Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study
Respiration · 2025
DOI: 10.1159/000549779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, 2025. Verfasst von Mingming Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respir…. Hauptthemen laut MEDLINE: Pulmonary Emphysema, Pneumonectomy, Prostheses and Implants. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Introduction
Available endobronchial valves (EBVs) for lung volume reduction in severe emphysema are limited in variety and predominantly feature complex metal-silicone designs (e.g., Zephyr®). This study aimed to introduce a novel, all-silicone endobronchial valve (ESV) designed to simplify manufacturing and potentially improve biocompatibility.
Methods
A preclinical study implanted ESVs or Zephyr® EBVs (1:1) into unilateral caudal lobes of 8 pigs, assessed using computed tomography, bronchoscopy, and necropsy over 6 weeks. A first-in-human (FIH) trial enrolled 3 severe emphysema patients (male, aged 48–72 years, collateral ventilation-negative). ESVs were placed using a bronchoscope under general anaesthesia. Outcomes included procedural success, safety, target lobar volume reduction, lung function, quality of life, and exercise capacity at baseline and 3 and 6 months.
Results
Preclinically, all valves (12 ESV, 12 Zephyr®) were successfully implanted and removed. Complete target lobe atelectasis occurred by 6 weeks in all animals, without major adverse events; localised granulation was observed. In the FIH trial, all ESVs were successfully deployed (procedure time: 5–20 min). Target lobar volume reductions occurred at 6 months in 2 of 3 cases (Case 1: 1.5 L, Case 2: 0.4 L). Emphysema volume decreased at 3 and 6 months. Lung function, quality of life, and exercise capacity showed trends toward improvement. One patient experienced an acute exacerbation of chronic obstructive pulmonary disease; no pneumothorax, pneumonia, or haemoptysis occurred.
Conclusion
Overall, ESV was shown to have an initial feasibility for endobronchial lung volume reduction in humans. Further studies are needed to evaluate the sustained effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of…
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Zitieren
APA
Deng, M., Zheng, Z., Tong, R., Huang, K., Yang, T., & Hou, G. (2025). Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study. Respiration. https://doi.org/10.1159/000549779
Vancouver
Deng M, Zheng Z, Tong R, Huang K, Yang T, Hou G. Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study. Respiration. 2025. doi:10.1159/000549779
BibTeX
@article{Deng2025,
author = {Deng, Mingming and Zheng, Ziwen and Tong, Run and Huang, Ke and Yang, Ting and Hou, Gang},
title = {Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study},
journal = {Respiration},
year = {2025},
doi = {10.1159/000549779}
}
EUVIMED